<DOC>
	<DOCNO>NCT02304991</DOCNO>
	<brief_summary>Primary Objective : To determine 36 month peanut SLIT early intervention subject age 1 4 year induce clinical desensitization . The primary outcome objective statistically significant difference challenge score treatment group versus placebo group DBPCFC ( Double blind placebo control food challenge ) perform 36 month peanut SLIT ( desensitization ) . A secondary outcome objective statistically significant difference challenge score treatment group versus placebo group DBPCFC perform 3 month discontinue therapy ( tolerance ) . Challenge score measure amount peanut protein participant able ingest successfully without symptom allergic reaction . [ Time Frame : Baseline , 39 month ] Secondary Objective : To examine change immune parameter associate peanut SLIT development clinical tolerance . Through objective , investigator seek understand molecular process SLIT affect immune system evaluation immune mechanism relationship clinical finding desensitization tolerance . The investigator delineate impact peanut SLIT subsequent cellular humoral response peanut protein : 1 ) peanut specific IgE , IgG , IgG4 response , 2 ) peanut specific basophil activation , 3 ) mast cell response skin prick testing , 4 ) specific T-cell cytokine response T regulatory cell ( TReg ) activation . The investigator anticipate effect peanut SLIT occur induction TRegs , conversion T cell allergic ( TH2 ) non-allergic ( TH1 ) lymphocyte response ( measure cytokine , antibody level , skin prick test size ) , change peanut-specific basophil activation , combination . [ Time Frame : Baseline , 39 month ]</brief_summary>
	<brief_title>FARE Peanut SLIT Early Tolerance Induction</brief_title>
	<detailed_description>Peanut allergy one common food allergy ; child develop allergy early life , outgrow risk severe life-ending anaphylactic reaction . There critical need proactive treatment peanut allergy investigator along others develop specific type immunotherapy act disease-modifying therapy . This SLIT study randomize , blind , placebo-controlled study . The primary outcome objective statistically significant difference challenge score treatment group versus placebo group DBPCFC perform 36 month peanut SLIT ( desensitization ) . A secondary outcome objective statistically significant difference challenge score treatment group versus placebo group DBPCFC perform 3 month discontinue therapy ( tolerance ) . Upon enrollment study , subject undergo qualify entry DBPCFC peanut protein confirm diagnosis peanut allergy establish baseline threshold level . Following positive DBPCFC , subject randomize 1:1 receive peanut SLIT therapy versus placebo duration 36 month . DBPCFC repeat active placebo subject 36 month assess desensitization 39 month assess tolerance . Outcome variables interest include peanut specific IgE , IgG , IgG4 , basophil activation , mast cell response skin prick testing , specific T-cell cytokine response T regulatory cell ( TReg ) activation .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<criteria>Written inform consent participant 's parent/guardian . Age 1248 month either sex , race , ethnicity . A peanut allergy diagnosis convince clinical history peanut allergy serum peanutspecific IgE [ UniCAP ] &gt; 0.35 kUA/L AND positive skin prick test peanut ( &gt; 3 mm negative control ) OR sensitize peanut ( base serum IgE [ UniCAP ] peanut &gt; 5 kUA/L ) AND positive skin prick test peanut ( &gt; 3 mm negative control ) know history ingestion peanut . A positive DBPCFC 1000 mg peanut enrollment . History severe anaphylaxis peanut , define hypoxia , hypotension , neurologic compromise ( cyanosis SpO2 &lt; 92 % stage , hypotension , confusion , collapse loss consciousness ) . Participation interventional study treatment food allergy past 6 month . Known oat , wheat , glycerin allergy . Eosinophilic inflammatory ( e.g . celiac ) gastrointestinal disease . Severe asthma ( 2007 NHLBI Criteria Steps 5 6 Appendix 2 ) . Inability discontinue antihistamine skin test DBPCFCs . Use omalizumab nontraditional form allergen immunotherapy ( e.g. , oral sublingual ) immunomodulator therapy ( include corticosteroid ) biologic therapy within past year . Use betablockers ( oral ) , angiotensinconverting enzyme ( ACE ) inhibitor , angiotensinreceptor blocker ( ARB ) calcium channel blocker . Significant medical condition ( e.g. , liver , kidney , gastrointestinal , cardiovascular , hematologic , pulmonary disease ) would make subject unsuitable induction food reaction .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>48 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Peanut</keyword>
	<keyword>Food Allergy</keyword>
</DOC>